Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft
Maria Pia Morelli, Emiliano Calvo, E. Ordonez Ordonez et al. · Journal of Clinical Oncology · 2011
Cited by 91 works. doi:10.1200/jco.2011.36.9678
Authors
- Maria Pia Morelli
- Emiliano Calvo
- E. Ordonez Ordonez
- Michael J. Wick
- Belén Rubio‐Viqueira
- Pedro Pablo Lopez-Casas
- Elizabeth M. Bruckheimer
- Antonio Calles
- David Sidransky
- Manuel M. Hidalgo
References
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
- An In vivo Platform for Translational Drug Development in Pancreatic Cancer
- Distant metastasis in adenoid cystic carcinoma of salivary origin
- Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group
- Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre
- Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
- Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study